JP7487421B2 - Ｐｒｍｔ５阻害剤 - Google Patents

Ｐｒｍｔ５阻害剤 Download PDF

Info

Publication number
JP7487421B2
JP7487421B2 JP2023535834A JP2023535834A JP7487421B2 JP 7487421 B2 JP7487421 B2 JP 7487421B2 JP 2023535834 A JP2023535834 A JP 2023535834A JP 2023535834 A JP2023535834 A JP 2023535834A JP 7487421 B2 JP7487421 B2 JP 7487421B2
Authority
JP
Japan
Prior art keywords
amino
methanone
methyl
dihydrofuro
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023535834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550530A (ja
Inventor
ブッカー，ション
ブルボー，マシュー・ポール
バトラー，ジョン・アール
グラッド，サンネ・オムホルト・シュローダー
ランマン，ブライアン・アラン
ロペス，パトリシア
マンオーニ，フランチェスコ
ペタス，リピング・エイチ
サルベアリー，イアン
タマヨ，ヌリア・エイ
ベステルゴード，ミッケル
ウィアーズ，ニコラス・アンソニー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2023550530A publication Critical patent/JP2023550530A/ja
Priority to JP2024075101A priority Critical patent/JP2024102236A/ja
Application granted granted Critical
Publication of JP7487421B2 publication Critical patent/JP7487421B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023535834A 2020-12-16 2021-12-15 Ｐｒｍｔ５阻害剤 Active JP7487421B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024075101A JP2024102236A (ja) 2020-12-16 2024-05-07 Ｐｒｍｔ５阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126416P 2020-12-16 2020-12-16
US63/126,416 2020-12-16
PCT/US2021/063540 WO2022132914A1 (en) 2020-12-16 2021-12-15 Prmts inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024075101A Division JP2024102236A (ja) 2020-12-16 2024-05-07 Ｐｒｍｔ５阻害剤

Publications (2)

Publication Number Publication Date
JP2023550530A JP2023550530A (ja) 2023-12-01
JP7487421B2 true JP7487421B2 (ja) 2024-05-20

Family

ID=79927288

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023535834A Active JP7487421B2 (ja) 2020-12-16 2021-12-15 Ｐｒｍｔ５阻害剤
JP2024075101A Pending JP2024102236A (ja) 2020-12-16 2024-05-07 Ｐｒｍｔ５阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024075101A Pending JP2024102236A (ja) 2020-12-16 2024-05-07 Ｐｒｍｔ５阻害剤

Country Status (17)

Country Link
US (2) US11845760B2 (https=)
EP (2) EP4263545B1 (https=)
JP (2) JP7487421B2 (https=)
KR (1) KR20230121820A (https=)
AR (1) AR124369A1 (https=)
AU (1) AU2021400942A1 (https=)
CA (1) CA3204823A1 (https=)
CL (1) CL2023001738A1 (https=)
CO (1) CO2023008167A2 (https=)
CR (1) CR20230310A (https=)
IL (1) IL303451A (https=)
JO (1) JOP20230138A1 (https=)
MX (1) MX2023007192A (https=)
PE (1) PE20231295A1 (https=)
TW (1) TW202233183A (https=)
UY (1) UY39565A (https=)
WO (1) WO2022132914A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024102236A (ja) * 2020-12-16 2024-07-30 アムジエン・インコーポレーテツド Ｐｒｍｔ５阻害剤

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2021086879A1 (en) 2019-10-28 2021-05-06 Tango Therapeutics, Inc. Compounds and methods of use
CN116568677A (zh) 2020-07-31 2023-08-08 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
TW202319046A (zh) * 2021-08-30 2023-05-16 美商安進公司 用於合成㖠啶衍生物及其中間體之方法
CA3255376A1 (en) * 2022-04-08 2023-10-12 Amgen Inc. CANCER TREATMENTS USING MTA-COOPERATED PRMT5 INHIBITORS
WO2024002263A1 (zh) * 2022-06-30 2024-01-04 南京明德新药研发有限公司 氨基取代的杂芳基衍生物及其应用
AU2023296592A1 (en) * 2022-07-01 2025-01-30 Cytosinlab Therapeutics Co., Ltd. Class of prmt5 inhibitors and use thereof
CN119013274A (zh) * 2022-07-26 2024-11-22 上海和誉生物医药科技有限公司 一种prmt5抑制剂及其制备方法和药学上的应用
AU2023319559B2 (en) * 2022-08-03 2026-04-16 Abbisko Therapeutics Co., Ltd. Nitrogen-containing fused three ring prmt5 inhibitor, and preparation method therefor and pharmaceutical use thereof
CN119730853A (zh) 2022-08-15 2025-03-28 阿斯利康(瑞典)有限公司 用于治疗癌症的mta协同prmt5抑制剂
JP2025529831A (ja) * 2022-08-18 2025-09-09 メッドシャイン ディスカバリー インコーポレイテッド アミド含有複素環誘導体とその使用
CN117658980A (zh) * 2022-09-08 2024-03-08 郑州同源康医药有限公司 双环类prmt5抑制剂
EP4588920A4 (en) * 2022-09-26 2026-01-28 Shanghai Apeiron Therapeutics Company Ltd NEW PRMT5 INHIBITOR AND ITS USE
IL319814A (en) * 2022-09-26 2025-05-01 Shanghai Apeiron Therapeutics Company Ltd A novel inhibitor of protein arginine methyltransferase 5 and its use
CN115677708B (zh) * 2022-10-19 2024-11-29 深圳万知达企业管理有限公司 一种吡咯并喹喔啉的制备方法
TW202440126A (zh) * 2022-11-30 2024-10-16 美商安進公司 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療
KR20250119589A (ko) * 2022-12-05 2025-08-07 암젠 인크 나프티리딘 화합물의 고체 형태
WO2024131901A1 (zh) * 2022-12-23 2024-06-27 深圳微芯生物科技股份有限公司 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用
CN116332856A (zh) * 2023-01-04 2023-06-27 荟达医药科技(上海)有限公司 一种4-哒嗪甲醇的合成方法
JP2026504889A (ja) 2023-01-18 2026-02-10 アンテンジーン・ディスカバリー・リミテッド Ｐｒｍｔ５阻害化合物およびその使用
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
CN120769934A (zh) * 2023-02-28 2025-10-10 美国安进公司 用于合成萘啶衍生物及其中间体的方法
CN121241054A (zh) * 2023-04-14 2025-12-30 北京双鹤润创科技有限公司 氮杂环羰基稠环衍生物及其用途
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4700025A1 (en) 2023-04-23 2026-02-25 Suzhou Genhouse Bio Co., Ltd. Amide compound, pharmaceutical composition comprising same, and use thereof
CN121358731A (zh) * 2023-05-17 2026-01-16 四川科伦博泰生物医药股份有限公司 三并环酰胺化合物、包含其的药物组合物及其制备方法和用途
US11845749B1 (en) 2023-07-13 2023-12-19 King Faisal University Substituted pyrido[4′,3′:5,6]pyrazino[1,2-a]indoles as anticancer agents
WO2025016323A1 (zh) 2023-07-14 2025-01-23 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
CN120943832A (zh) 2023-08-02 2025-11-14 成都微芯药业有限公司 杂环炔基取代的酰胺衍生物、其制备方法及其应用
AU2024319888A1 (en) 2023-08-09 2026-02-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Heteroaryl compound, preparation method therefor, and use thereof in medicine
CN121127472A (zh) 2023-08-18 2025-12-12 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
AU2024356380A1 (en) * 2023-10-06 2026-04-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2025077856A1 (en) * 2023-10-12 2025-04-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Tricyclic-carbonyl-nitrogen heterocyclic derivatives and use thereof
US20250154172A1 (en) * 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025166215A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025166274A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025190395A2 (en) * 2024-03-14 2025-09-18 Pharmaengine, Inc. Mta-cooperative prmt5 inhibitor
WO2025215153A1 (en) * 2024-04-10 2025-10-16 Ryvu Therapeutics S.A. Prmt5 inhibitors
WO2025257104A1 (en) 2024-06-10 2025-12-18 Sandvik Mining And Construction Tools Ab Diamond and cemented carbide composite material
WO2025265110A1 (en) 2024-06-21 2025-12-26 Amgen Inc. Oral pharmaceutical compositions comprising a naphthyridine compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032859A1 (en) 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573932B (zh) 2014-08-22 2019-07-30 默克专利股份公司 吲唑类
JP7787819B2 (ja) * 2020-02-12 2025-12-17 アムジェン インコーポレイテッド 新規ｐｒｍｔ５阻害剤
AU2021400942A1 (en) * 2020-12-16 2023-07-06 Amgen Inc. PRMT5 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032859A1 (en) 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024102236A (ja) * 2020-12-16 2024-07-30 アムジエン・インコーポレーテツド Ｐｒｍｔ５阻害剤

Also Published As

Publication number Publication date
EP4263545A1 (en) 2023-10-25
US20220194955A1 (en) 2022-06-23
AU2021400942A9 (en) 2024-10-24
US11845760B2 (en) 2023-12-19
TW202233183A (zh) 2022-09-01
CO2023008167A2 (es) 2023-07-21
IL303451A (en) 2023-08-01
UY39565A (es) 2022-06-30
KR20230121820A (ko) 2023-08-21
JP2023550530A (ja) 2023-12-01
CN116888120A (zh) 2023-10-13
EP4732837A2 (en) 2026-04-29
AR124369A1 (es) 2023-03-22
CL2023001738A1 (es) 2023-11-17
US20240092794A1 (en) 2024-03-21
PE20231295A1 (es) 2023-08-22
AU2021400942A1 (en) 2023-07-06
JP2024102236A (ja) 2024-07-30
CR20230310A (es) 2023-09-01
JOP20230138A1 (ar) 2023-06-14
MX2023007192A (es) 2023-07-03
CA3204823A1 (en) 2022-06-23
WO2022132914A1 (en) 2022-06-23
EP4263545B1 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
JP7487421B2 (ja) Ｐｒｍｔ５阻害剤
EP4251624B1 (en) Tricyclic carboxamide derivatives as prmt5 inhibitors
JP7787819B2 (ja) 新規ｐｒｍｔ５阻害剤
JP2024508235A (ja) 三環－アミド－二環ｐｒｍｔ５阻害剤
JP7254094B2 (ja) Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体
TWI804295B (zh) 作為甲硫胺酸腺苷轉移酶抑制劑的化合物、其製備方法及應用
CN116888120B (zh) Prmt5抑制剂
EA048318B1 (ru) Ингибиторы prmt5
HK40101523B (en) Tricyclic carboxamide derivatives as prmt5 inhibitors
HK40101523A (en) Tricyclic carboxamide derivatives as prmt5 inhibitors
AU2024284667A1 (en) Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230919

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240508

R150 Certificate of patent or registration of utility model

Ref document number: 7487421

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150